Medicare adds 15 drugs, including Ozempic and Wegovy, to its price negotiation list, aiming to save billions. Incoming Trump administration will finalize details, but obesity treatment remains uncovered under Medicare rules.

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of